Deucravacitinib: TYK2 Inhibition for Psoriasis

Overview / Definition Deucravacitinib is an oral, selective inhibitor of the enzyme tyrosine kinase 2 (TYK2), which plays a critical role in the inflammatory signaling pathways associated with psoriasis. By selectively inhibiting TYK2, deucravacitinib modulates the immune response and reduces the pathological effects of psoriasis. It is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Epidemiology Psoriasis affects approximately 2-3% of the global population, with a higher prevalence in Caucasians compared to other ethnic groups. The onset of psoriasis typically occurs in two peaks: the first peak occurs in early adulthood (ages 15-30) and the second peak in middle age (ages 50-60). Risk factors include a family history of psoriasis, obesity, smoking, and certain comorbidities such as psoriatic arthritis. Pathophysiology / Mechanism The pathophysiology of psoriasis is characterized by an inappropriate activation of the immune system, particularly involving CD4+ T cells, which produce pro-inflammatory cytokines such as IL-17 and IL-23. Deucravacitinib acts by specifically inhibiting TYK2, which is a key mediator in the signaling pathways of these cytokines. This inhibition leads to: Reduced production of inflammatory cytokines. Decreased activation of T cells and dendritic cells. Improvement in keratinocyte hyperproliferation and inflammation. By targeting this pathway, deucravacitinib provides a novel mechanism of action distinct from other systemic treatments for psoriasis. Clinical Presentation Patients with psoriasis typically present with: Well-defined erythematous plaques covered with silvery scales. Common locations include the elbows, knees, scalp, and lower back. Accompanied by pruritus, which can be severe. Possible nail involvement (pitting, onycholysis) and joint symptoms indicating psoriatic arthritis. Clinical severity can range from mild localized patches to extensive